BACKGROUND: The evaluation of OCT3 during anti-VEGF therapy. METHODS: A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months. RESULTS: The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation. CONCLUSION: During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.
BACKGROUND: The evaluation of OCT3 during anti-VEGF therapy. METHODS: A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months. RESULTS: The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation. CONCLUSION: During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.
Authors: Lelia A Paunescu; Joel S Schuman; Lori Lyn Price; Paul C Stark; Siobahn Beaton; Hiroshi Ishikawa; Gadi Wollstein; James G Fujimoto Journal: Invest Ophthalmol Vis Sci Date: 2004-06 Impact factor: 4.799
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan Journal: Toxicol Pathol Date: 1999 Sep-Oct Impact factor: 1.902
Authors: Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller Journal: Arch Ophthalmol Date: 2002-03
Authors: Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams Journal: Ophthalmology Date: 2006-02-14 Impact factor: 12.079
Authors: Dorothy M Gohdes; Appathurai Balamurugan; Barbara A Larsen; Christopher Maylahn Journal: Prev Chronic Dis Date: 2005-06-15 Impact factor: 2.830
Authors: Christian Ahlers; Erich Götzinger; Michael Pircher; Isabelle Golbaz; Franz Prager; Christopher Schütze; Bernhard Baumann; Christoph K Hitzenberger; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2009-09-24 Impact factor: 4.799
Authors: Gesine B Jaissle; Peter Szurman; Nicolas Feltgen; Bernhard Spitzer; Amelie Pielen; Matus Rehak; Georg Spital; Heinrich Heimann; Carsten H Meyer Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-08-18 Impact factor: 3.117